SCHEDULE: Vanguard Divests Kymera Stake Amid Internal Realignment

The Vanguard Group reported a 0% beneficial ownership in Kymera Therapeutics Inc. following an internal realignment, with subsidiaries now reporting separately.

Summary

• The Vanguard Group filed an Amendment No. 4 to Schedule 13G for Kymera Therapeutics Inc.
• As of March 13, 2026, The Vanguard Group reported 0.00 shares beneficially owned, representing 0% of the class of Common Stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities previously reported.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Kymera Therapeutics Inc. as the change in beneficial ownership by The Vanguard Group is attributed to an internal corporate realignment rather than a direct investment decision related to Kymera's performance or prospects.

Negatives

• The Vanguard Group, a prominent institutional investor, no longer holds any direct beneficial ownership in Kymera Therapeutics Inc.
• While attributed to an internal realignment, a complete divestment by a large fund manager could be perceived negatively by some investors, potentially leading to short-term market uncertainty.

Industry Context

StockSavvy.ai notes that institutional ownership changes, especially from major players like The Vanguard Group, are closely watched. While this filing attributes the change to an internal realignment rather than a strategic divestment based on Kymera's performance, it still represents a shift in how a significant portion of institutional capital is managed and reported concerning Kymera. This could lead to a perception of reduced institutional interest, even if the underlying capital remains invested through Vanguard's subsidiaries.

Stakeholder Impact

• Shareholders: Existing shareholders might perceive a reduction in institutional backing from The Vanguard Group, though the underlying capital may still be managed by Vanguard's disaggregated entities. This could lead to short-term uncertainty or minor selling pressure.
• Investment Community: Financial analysts and other institutional investors will need to adjust their tracking of Vanguard's aggregate holdings in Kymera, now needing to consider the holdings of its separately reporting subsidiaries.

Key Dates

Recommendation

The filing indicates a technical change in beneficial ownership reporting by The Vanguard Group due to an internal realignment, rather than a strategic divestment based on Kymera's fundamentals. While the immediate market reaction might be negative due to the headline of 0% ownership, the underlying investment thesis for Kymera remains unchanged by this specific filing. Investors should hold and monitor subsequent filings from Vanguard's subsidiaries to understand the true aggregate institutional exposure.

Keywords

Kymera Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Ownership Change, Internal Realignment